Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (9)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Porzecanski, I.
Right arrow Articles by Bowton, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Porzecanski, I.
Right arrow Articles by Bowton, D. L.
Related Content
Right arrow Contemporary Reviews in Critical Care Medicine
(Chest. 2006;130:597-604.)
© 2006 American College of Chest Physicians

Diagnosis and Treatment of Ventilator-Associated Pneumonia*

Ilana Porzecanski, MD and David L. Bowton, MD, FCCP

* From the Section on Critical Care, Department of Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, NC.

Correspondence to: David L. Bowton, MD, FCCP, Section on Critical Care, Department of Anesthesiology, Medical Center Blvd, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1009; e-mail: dbowton{at}wfubmc.edu

Abstract

Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in the ICU. Patients who acquire VAP have higher mortality rates and longer ICU and hospital stays. Because there are other potential causes of fever, leukocytosis, and pulmonary infiltrates, clinical diagnostic criteria are overly sensitive in the diagnosis of VAP. Employing quantitative cultures of bronchopulmonary secretions in the diagnostic algorithm leads to less antibiotic use and probably to lower mortality. With respect to microbiologic diagnosis, it is not clear that the use of a particular sampling method (bronchoscopic or nonbronchoscopic), when quantitatively cultured, is associated with better outcomes. Delayed administration of adequate antibiotic therapy is linked to an increased mortality rate. Hence, the focus of initial antibiotic therapy should be to rapidly provide antibiotic coverage for all likely pathogens and to then narrow or focus the antibiotic spectrum based on the results of quantitative cultures. Eight days of antibiotic therapy appears equivalent to 15 days of therapy except when treating nonlactose-fermenting Gram-negative organisms. In this latter situation, longer treatment durations appear to reduce the risk of recrudescence after discontinuation of antibiotic therapy. A guideline-based approach using the local hospital or ICU antibiogram can increase the likelihood that adequate initial antibiotic therapy is used and reduce the overall use of antibiotics and the associated selection pressure for multidrug-resistant organisms.

Key Words: antibiotics • drug therapy • diagnosis • nosocomial pneumonia • review • treatment • ventilator-associated pneumonia




This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
C. Van De Wauwer, D. Van Raemdonck, G. M. Verleden, L. Dupont, P. De Leyn, W. Coosemans, P. Nafteux, and T. Lerut
Risk factors for airway complications within the first year after lung transplantation
Eur. J. Cardiothorac. Surg., April 1, 2007; 31(4): 703 - 710.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.